Bank of New York Mellon Corp Buys New Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Bank of New York Mellon Corp bought a new stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 20,232 shares of the company’s stock, valued at approximately $356,000.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada raised their price objective on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th.

Contineum Therapeutics Price Performance

Shares of NASDAQ CTNM opened at $18.19 on Thursday. Contineum Therapeutics, Inc. has a twelve month low of $13.27 and a twelve month high of $22.00. The firm has a 50-day simple moving average of $18.80.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, equities research analysts forecast that Contineum Therapeutics, Inc. will post -2.04 EPS for the current year.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).